Bioreactors in Tissue Engineering: Scientific Challenges and Clinical Perspectives

Wendt, David; Riboldi, Stefania Adele; Cioffi, Margherita; Martin, Ivan

doi:10.1007/978-3-540-69357-4_1

Cited by 35 publications

(24 citation statements)

References 89 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…V,ðÀDVcÞ þ u,Vc ¼ r A (11) where, c A is the concentration of the species (mol/m 3 ), r A is the rate of reaction of the species under consideration (mol/m 3 s), D is the diffusivity of the species (m 2 /s), and u is velocity (m/s). The rate expression (r A ) defined in the convective-diffusion equation is representative of the rate of nutrient consumption in the system.…”

Section: Flow Characterizationmentioning

confidence: 99%

Application of computational fluid dynamics in tissue engineering

Patrachari¹,

Podichetty²,

Madihally³

2012

Journal of Bioscience and Bioengineering

View full text Add to dashboard Cite

Section: Flow Characterizationmentioning

confidence: 99%

Application of computational fluid dynamics in tissue engineering

Patrachari¹,

Podichetty²,

Madihally³

2012

Journal of Bioscience and Bioengineering

View full text Add to dashboard Cite

“…As reported on several occasions, bioreactor culture can be an important step in the TE product development cycle, allowing a reduction of the product variability [56][57][58]. A plethora of bioreactor setups are available on the market, from complete industrially developed closed systems to modular research variants.…”

Section: Application To Regenerative Orthopaedicsmentioning

confidence: 99%

Regenerative orthopaedics: in vitro, in vivo … in silico

Geris

2014

International Orthopaedics (SICOT)

View full text Add to dashboard Cite

In silico, defined in analogy to in vitro and in vivo as those studies that are performed on a computer, is an essential step in problem solving and product development in classical engineering fields. The use of in silico models is now slowly easing its way into medicine. In silico models are already used in orthopaedics for the planning of complicated surgeries, personalised implant design and the analysis of gait measurements. However, these in silico models often lack the simulation of the response of the biological system over time. In silico models focusing on the response of the biological systems are in full development. This review starts with an introduction into in silico models of orthopaedic processes. Special attention is paid to the classification of models according to their spatiotemporal scale (gene/protein to population) and the information they were built on (data vs hypotheses). Subsequently, the review focusses on the in silico models used in regenerative orthopaedics research. Contributions of in silico models to an enhanced understanding and optimisation of four key elements -cells, carriers, culture and clinics -are illustrated. Finally, a number of challenges are identified, related to the computational aspects but also to the integration of in silico tools in clinical practice.

show abstract

“…Incorporated into this device are rodent cardiomyocytes and fibroblasts grown on scaffolds with a parallel array of perfused channels to mimic the capillary network. Blood was mimicked by supplemented media and the model used to assess a number of parameters such as the impact of perfusion rates of oxygen on viable cell density to the define the conditions needed to culture cardiac constructs with clinically relevant thickness [18].…”

Section: Status Of Bioreactors In the Development Of In Vitro Modelsmentioning

confidence: 99%

The use of bioreactors as in vitro models in pharmaceutical research

Ginai

Elsby

Hewitt

et al. 2013

Drug Discovery Today

View full text Add to dashboard Cite

Word TeaserThe development of dynamic 3D bioreactor based systems as in vitro models for use in DMPK studies. Author BiographiesMaaria Ginai graduated with a first Class Bachelors degree with honours in Biomedical Science from the University of Kent (UK) in 2010. She is currently studying a BBSRC CASEfunded PhD at the Centre for Biological Engineering at Loughborough University in the area of bioartificial device progression to in vitro models for use in the pharmaceutical industry. This project is supported by AstraZeneca.Christopher J. Hewitt has a first Class Bachelors degree in Biology from Royal Holloway College, University of London (UK) and a PhD in Chemical Engineering from the University of Birmingham (UK). He is Director of the £7.3M EPSRC Doctoral Training Centre in Regenerative Medicine and co-founder of the £2M Centre for Biological Engineering at Loughborough University (UK). He also leads the Cell Technologies research group whose work spans the Engineering/Life science interface seeking to understand the interaction of the organism with the engineering environment within such diverse areas as microbial fermentation, bio-transformation, cell culture and mostly recently regenerative medicine bioprocessing.Karen Coopman has a first Class Bachelors degree in Pharmacology from the University of Bristol (UK) and a PhD from the Department of Pharmacy and Pharmacology at the University of Bath (UK). She was appointed to a lectureship at Loughborough University, where she is the Operations Manager of the EPSRC-funded Doctoral Training Centre in Regenerative Medicine. She co-leads the Cell Technologies research group within University's Centre for Biological Engineering and is currently a member of the EPSRC's Early Career Forum in Manufacturing Research. The overarching themes of Karen's research are the manufacture of cellular therapies and the use of cells in the drug discovery process. AbstractBringing a new drug to market is costly in terms of capital and time investments, and any development issues encountered in late stage clinical trials may often be due to in vitro -in vivo extrapolations (IVIVE) not accurately reflecting clinical outcome. In the discipline of drug metabolism and pharmacokinetics (DMPK), current in vitro cellular methods do not provide the 3D structure and function of organs found in vivo, so new dynamic methods need to be established to aid improvement of IVIVE. This review will highlight the importance of model progression into dynamic systems for use within drug development, focussing on devices developed currently in the areas of the liver and blood-brain barrier, and the potential to develop models for other organ systems such as the kidney.

show abstract

Bioreactors in Tissue Engineering: Scientific Challenges and Clinical Perspectives

Cited by 35 publications

References 89 publications

Application of computational fluid dynamics in tissue engineering

Application of computational fluid dynamics in tissue engineering

Regenerative orthopaedics: in vitro, in vivo … in silico

The use of bioreactors as in vitro models in pharmaceutical research

Contact Info

Product

Resources

About